Keyphrases
Adverse Drug Reaction
100%
Advanced Therapy Medicinal Products
49%
Clinical Trials
46%
Off-label Use
39%
European Union
38%
Clinical Practice
38%
Rituximab
32%
Elderly People
32%
Spain
32%
Acute Myocardial Infarction
29%
United States
29%
Pharmacovigilance
26%
Advanced Therapies
25%
BNT162b2
23%
Marketing Authorization
22%
Reactogenicity
22%
Potentially Inappropriate Medication
19%
Inappropriate Prescribing
19%
Secondary Prevention
19%
ChAdOx1
19%
Pediatric Hematology
19%
Tertiary Hospital
18%
Polypharmacy
18%
Comorbidity
18%
European Countries
17%
Spontaneous Reporting
16%
Older Patients
16%
Pharmacovigilance System
14%
Elderly Patients
14%
Hospital Physicians
13%
β-lactam Antibiotics
13%
Pacientes
13%
Hip Fracture
13%
Drug Provocation Test
13%
Systemic Lupus Erythematosus
12%
Electronic Medical Records
12%
Immunogenicity
12%
Hospital Setting
12%
Drug Treatment
12%
Clinical Development
11%
Spontaneous Reports
11%
Regulatory Framework
11%
Multiple Sclerosis
11%
Adverse Reactions
11%
SARS-CoV-2 Infection
11%
STOPP Criteria
11%
Older People
11%
Patient Register
11%
Multicentric
11%
Real-world Practice
10%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Drug Reaction
90%
Clinical Trial
45%
Adverse Event
43%
Retrospective Study
42%
Pharmacovigilance
40%
Off-Label Use
39%
Rituximab
34%
Acute Heart Infarction
31%
Anticoagulant Agent
30%
Disease
26%
SARS Coronavirus
26%
Polypharmacy
21%
Receptor
19%
Hip Fracture
19%
Cardiovascular Risk
19%
Infection
18%
Immunogenicity
16%
Prevalence
15%
Acetylsalicylic Acid
15%
Observational Study
14%
Cohort Study
14%
Prospective Study
13%
Multiple Chronic Conditions
13%
Immunoassay
13%
Beta Lactam Antibiotic
13%
Diabetes Mellitus
13%
Provocation Test
13%
Pharmacotherapy
12%
Remission
12%
Interferon
11%
Systemic Lupus Erythematosus
10%
Kidney Disease
10%
Beta Adrenergic Receptor Blocking Agent
10%
Beta Lactam
10%
Hydroxychloroquine
10%
Acute Kidney Failure
9%
Psychotropic Agent
9%
Adrenergic Receptor Blocking Agent
9%
Biological Product
9%
Infection
9%
Orphan Drug
9%
Pharmacoepidemiology
9%
Diseases
9%
Clinical Pharmacology
9%
Heart Infarction
9%
Adverse Event
9%
Indicator
9%
Vaccine
9%
Messenger RNA
9%
Benzodiazepine
9%
Medicine and Dentistry
Advanced Therapy
39%
Severe Acute Respiratory Syndrome Coronavirus 2
24%
Reactogenicity
22%
Clinical Trial
22%
Adverse Event
22%
Health Care Cost
20%
Antithrombotic
20%
Retrospective Study
20%
Reimbursement
19%
Adverse Drug Reaction
19%
Receptor Binding
17%
Immunogenicity
16%
Patient
14%
Infection
13%
Malignant Neoplasm
13%
Diseases
13%
Observational Study
13%
Drug Therapy
12%
Neutralization
12%
Orphan Drug
12%
Medicine
11%
B Cell
11%
Immunoassay
11%
Therapeutic Procedure
10%
Human Immunoglobulin
9%
Coronary Angiography
9%
Elderly Population
9%
Immunoglobulin
9%
Anticoagulation
9%
Acute Kidney Injury
9%
Hospital
9%
Rituximab
9%
Hydroxychloroquine
9%
Programmed Death-Ligand 1
9%
COVID-19 Vaccination
9%
Off-Label Use
9%
Acute Heart Infarction
9%
Asthma
9%
Cardiovascular Risk
9%
Provocation Test
9%
β-Lactam antibiotic
9%
Nephropathy
9%
Atrial Fibrillation
9%
Electronic Nose
9%
Decision Making
9%
Messenger RNA
9%
Breathing
9%
Myositis
9%
Heart Muscle Revascularization
9%
Hip Fracture
9%
